EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma

Vivian Changying Jiang, Yang Liu, Junwei Lian, Shengjian Huang, Alexa Jordan, Qingsong Cai, Ruitao Lin, Fangfang Yan, Joseph McIntosh, Yijing Li, Yuxuan Che, Zhihong Chen und 9 weitere

Journal of Clinical Investigation · 01.02.2023 · 133 (3)

DOI: 10.1172/jci165694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.02.2023. Verfasst von Vivian Changying Jiang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma and. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton's tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a major clinical challenge. We here report that MALT1 is one of the top overexpressed genes in ibrutinib-resistant MCL cells, while expression of CARD11, which is upstream of MALT1, is decreased. MALT1 genetic knockout or inhibition produced dramatic defects in MCL cell growth regardless of ibrutinib sensitivity. Conversely, CARD11-knockout cells showed antitumor effects only in ibrutinib-sensitive cells, suggesting that MALT1 overexpression could drive ibrutinib resistance via bypassing BTK/CARD11 signaling. Additionally, BTK knockdown and MALT1 knockout markedly impaired MCL tumor migration and dissemination, and MALT1 pharmacological inhibition decreased MCL cell viability, adhesion, and migration by suppressing NF-κB, PI3K/AKT/mTOR, and integrin signaling. Importantly, cotargeting MALT1 with safimaltib and BTK with pirtobrutinib induced potent anti-MCL activity in ibrutinib-resistant MCL cell lines and patient-derived xenografts. Therefore, we conclude that MALT1 overexpression associates with resistance to BTK inhibitors in MCL, targeting abnormal MALT1 activity could be a promising therapeutic strategy to overcome BTK inhibitor resistance, and cotargeting of MALT1 and BTK should improve MCL treatment efficacy and durability as well as patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Tyrosine KinasesLymphoma, Mantle-CellHumansAdultAgammaglobulinaemia Tyrosine KinaseCell Line, TumorPhosphatidylinositol 3-KinasesDrug Resistance, NeoplasmProtein Kinase InhibitorsMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinPyrazoles

Stichwörter der Autor:innen

Drug therapyHematologyLymphomasSignal transductionTherapeutics

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein-Tyrosine KinasesPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinpirtobrutinibPyrazolesMALT1 protein, human

Autor:innen und Institutionen

  • Department of Lymphoma and Myeloma and.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Förderung

  • NCI NIH HHS
  • NIH

Zitieren

APA

Jiang, V. C., Liu, Y., Lian, J., Huang, S., Jordan, A., Cai, Q., Lin, R., Yan, F., McIntosh, J., Li, Y., Che, Y., Chen, Z., Vargas, J., Badillo, M., Bigcal, J. N., Lee, H. H., Wang, W., Yao, Y., Nie, L., …, & Wang, M. (2023). Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. Journal of Clinical Investigation, 133(3). https://doi.org/10.1172/jci165694

Vancouver

Jiang VC, Liu Y, Lian J, Huang S, Jordan A, Cai Q, et al. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. Journal of Clinical Investigation. 2023;133(3). doi:10.1172/jci165694

BibTeX
@article{Jiang2023,
  author = {Jiang, Vivian Changying and Liu, Yang and Lian, Junwei and Huang, Shengjian and Jordan, Alexa and Cai, Qingsong and Lin, Ruitao and Yan, Fangfang and McIntosh, Joseph and Li, Yijing and Che, Yuxuan and Chen, Zhihong and Vargas, Jovanny and Badillo, Maria and Bigcal, John Nelson and Lee, Heng-Huan and Wang, Wei and Yao, Yixin and Nie, Lei and Flowers, Christopher R and Wang, Michael},
  title = {Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {3},
  doi = {10.1172/jci165694}
}
Kostenlos starten →